Companion diagnostics

Companion diagnostics are assays that measure levels of proteins, genes or specific mutations....

Companion diagnostics are assays that measure levels of proteins, genes or specific mutations, enabling patient selection and specific therapy to be administered, and its therapeutic effects to be measured.Report: Companion Diagnostic Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Companion diagnostics are assays that measure levels of proteins, genes or specific mutations, enabling patient selection and specific therapy to be administered, and its therapeutic effects to be measured.

Development of companion diagnostics, whereby molecular assays that measure levels of proteins, genes or specific mutations are used to provide a specific therapy for an individual's condition by stratifying disease status, selecting the proper medication and tailoring dosages to that patient's specific needs.

Additionally, such methods might be used to assess a patient's risk factor for a number of conditions and tailor individual preventative treatment approaches.

The development risk and time to market associated with drug candidates make the development of a companion diagnostic significantly less attractive to major diagnostics manufacturers than the revenues they generate from their traditional target market of clinical laboratories.

Companion diagnostics have the potential to reduce payers’ costs in the long term by providing the precise diagnostics required to avoid unnecessary or ineffective treatments, prevent adverse events, develop prevention strategies, and deliver more effective, targeted therapeutics.

A trend towards pay for performance could accelerate the adoption of personalized medicine, if clinical data shows that targeted diagnostics and therapies reduce payers’ costs.

Read: more on companion diagnostic deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Companion Diagnostic Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Example companion diagnostic deal from Current Agreements life sciences partnering, M&A and financing deals database:

Collaborative R&D agreement for compounds and companion diagnostics for treatment of pain

Genentech, Xenon Pharmaceuticals

Jan 9, 2012

Xenon in a strategic alliance with Genentech to discover and develop compounds and companion diagnostics for the potential treatment of pain.   Xenon and Genentech will collaborate on the discovery of new therapeutic approaches for treating pain.

Genentech has an exclusive license to compounds and a non-exclusive license to diagnostics from Xenon for development and commercialization of products.

Xenon will receive an undisclosed upfront payment, research funding and is eligible to receive research, development and commercialization milestone payments, totaling up to $646 million for multiple products and indications.

In addition, Xenon will receive royalties on sales of products resulting from the collaboration.

 

For more information about this and hundreds more companion diagnostic deals:

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Report: Companion Diagnostic Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Report: Companion Diagnostic Partnering Terms and Agreements

Report: Personalized Medicine Partnering Terms and Agreements

Read: more on companion diagnostic deals in pharma, biotech, life science partnering deal news, insights and glossary

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database - includes comprehensive coverage of all deals and alliances for the top 50 pharma companies – find out more

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Print Friendly, PDF & Email